Protagonist Therapeutics (PTGX) Other Non Operating Income (2016 - 2026)
Protagonist Therapeutics (PTGX) posted Other Non Operating Income of $53000.0 for Q1 2026, up 235.9% sequentially from -$39000.0 in Q4 2025, and down 35.37% YoY from $82000.0 in Q1 2025.
Powered by 
Analysis
Protagonist Therapeutics (PTGX) Other Non Operating Income (2016 - 2026) Analysis & Trends
Protagonist Therapeutics has reported Other Non Operating Income for 10 years, with the latest figure at $53000.0 in Q1 2026.
- Quarterly Other Non Operating Income fell 35.37% year-over-year to $53000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $83000.0 (up 101.79% YoY) and the FY2025 annual result came in at $112000.0, up 102.36% from the prior year.
- Other Non Operating Income improved to $53000.0 in Q1 2026 per PTGX's latest filing, from -$39000.0 in the prior quarter.
- Over five years, Other Non Operating Income peaked at $141000.0 in Q3 2024 and troughed at -$5.0 million in Q4 2024.
- A 5-year average of -$286176.5 and a median of $13000.0 in 2022 frame the typical range for Other Non Operating Income.
- The sharpest annual moves came in 2022 and 2024: Other Non Operating Income surged 646.15% in 2022, then slumped 11390.91% in 2024.
- Over 5 years, Other Non Operating Income stood at $71000.0 in 2022, then tumbled by 38.03% to $44000.0 in 2023, then plunged by 11390.91% to -$5.0 million in 2024, then jumped by 99.21% to -$39000.0 in 2025, then jumped by 235.9% to $53000.0 in 2026.
- According to Business Quant data, Other Non Operating Income over the past three periods registered $53000.0, -$39000.0, and $33000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.62 Bn | 131.77 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.73 Bn | 77.73 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.53 Bn | 58.35 Bn | 1.37 Bn |
| 4 | Moderna | 58.23 Bn | 53.09 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - |
| 6 | BeOne Medicines | 40.03 Bn | 34.93 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.50 Bn | 32.19 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.52 Bn | 27.68 Bn | - |
| 9 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn |
| 10 | Protagonist Therapeutics | 9.61 Bn | 9.61 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -81,000.00 |
| Mar 31, 2026 | 53,000.00 |
| Dec 31, 2025 | 4.63 Mn |
| Sep 30, 2025 | 33,000.00 |
| Jun 30, 2025 | 36,000.00 |
| Mar 31, 2025 | 82,000.00 |
| Dec 31, 2024 | 2.48 Mn |
| Sep 30, 2024 | 141,000.00 |
| Jun 30, 2024 | 97,000.00 |
| Mar 31, 2024 | -19,000.00 |
| Dec 31, 2023 | 2.45 Mn |
| Sep 30, 2023 | -31,000.00 |
| Jun 30, 2023 | -19,000.00 |
| Mar 31, 2023 | -195,000.00 |
| Dec 31, 2022 | 71,000.00 |
| Sep 30, 2022 | -86,000.00 |
| Jun 30, 2022 | -78,000.00 |
| Mar 31, 2022 | 13,000.00 |
| Dec 31, 2021 | -13,000.00 |
| Jun 30, 2021 | -57,000.00 |